In The News

Heart Failure Outcomes With Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: Results of the EMPA-REG OUTCOME Trial

January 26, 2016. This follow-on study to the EMPA-REG (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes) OUTCOME trial in patients with type 2 diabetes (T2D) and high cardiovascular risk evaluated heart failure–related outcomes across all patient groups (empagliflozin 10 mg, 25 mg, or placebo; N=7,020). Investigators found that treatment with empagliflozin improved heart failure–related hospitalization and cardiovascular mortality rates (5.7% in patients treated with empagliflozin, 8.5% in placebo; P<0.001).

Sustained Efficacy of Insulin Pump Therapy versus Multiple Daily Injections in Type 2 Diabetes: 12-month Data From the OpT2mise Randomized Trial

February 8, 2016. This randomized, controlled study was developed to compare insulin pump versus multiple daily injection (MDI) therapy in patients with type 2 diabetes receiving basal and prandial insulin. Following a 2-month dose-optimization period, patients (N=331) with elevated A1C levels (mean 9.0%) were randomized to pump therapy or MDI for 6 months. Investigators found significantly reduced A1C levels in pump compared with MDI patients (-1.1% vs -0.4%, respectively; P<0.001). These improvements were maintained in the pump therapy group through 12 months.

Markers of Beta-Cell Failure Predict Poor Glycemic Response to GLP-1 Therapy in Type 2 Diabetes

February 2016. This prospective analysis evaluated clinical responses in 620 patients with type 2 diabetes treated with a GLP-1 receptor agonist (GLP-1RA) to determine whether clinical characteristics and markers of beta-cell failure are associated with individual response to GLP-1RA use. Participants were required to have an A1C level >7.5% and were followed for 6 months.

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the Beta-Cell–Centric Classification Schema

February 2016. This article issues an urgent call to review the current diabetes mellitus (DM) classification system. The authors argue for a new, beta-cell–centric classification of DM, a model that presupposes that all DM originates from a final common denominator: abnormal pancreatic beta-cell function. Interactions between genetically predisposed beta-cells and a number of factors lead to a range of hyperglycemic phenotypes within the DM spectrum.

Antidepressant Medication Use and Glycemic Control in Co-Morbid Type 2 Diabetes and Depression

January 7, 2016. Depression is highly prevalent in patients with diabetes and is associated with multiple negative outcomes. This retrospective cohort study (n=1399) evaluated patients with concurrent type 2 diabetes and depression who attended ambulatory primary care visits to assess whether the use of antidepressant medications was associated with good glycemic control (defined as A1C

American Association of Clinical Endocrinologists/American College of Endocrinology Release 2016 Comprehensive Type 2 Diabetes Management Algorithm

January 5, 2016. The American Association of Clinical Endocrinologists (AACE), in conjunction with the American College of Endocrinology (ACE), has announced the publication of its 2016 update of the AACE/ACE Comprehensive Diabetes Management Algorithm and Executive Summary as a clinical guide for physicians managing the care of patients with type 2 diabetes. The 2016 algorithm considers new therapies, disease management approaches, and key clinical data.

Do Patients With Newly Diagnosed Diabetes Benefit From Early Specialist Care?

January 2016. This large, population-based, propensity score-matched cohort study used administrative health data from Ontario, Canada (1998-2006, N=79,020) to evaluate cardiovascular (CV) mortality and events in patients who received endocrinologist care in the year following diabetes diagnosis, compared with patients who received primary care alone.

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes

December 17, 2015. This randomized, crossover, noninferiority study found that intranasal glucagon was highly effective at treating insulin-induced hypoglycemia. Patients from 8 clinical centers (N=75) were evaluated following receipt of intranasal glucagon (3 mg) or intramuscular glucagon (1 mg). Success was defined as achieving glucose levels ≥70 mg/dL or ≥20 mg/dL from the glucose low point within 30 minutes of glucagon administration. Success rates (and mean time to success) with intranasal and intramuscular glucagon, respectively were 98.7% (16 minutes) and 100% (13 minutes).

FDA Approves Basaglar, the First “Follow-on” Insulin Glargine Product to Treat Diabetes

December 16, 2015. The US Food and Drug Administration (FDA) has approved insulin Basaglar (insulin glargine injection), the first insulin product approved through an abbreviated approval pathway. This application relied, in part, on the FDA’s finding of safety and effectiveness for Lantus (insulin glargine injection).